A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with moderate to severe atopic dermatitis

EASI50 response, defined as a decrease in Eczema Area and Severity Index (EASI) of at least 50% compared to baseline

Kusajili – Centralise les essais cliniques mondiaux